EP0944594A4 - Inhibiteurs de l'activite enzymatique de l'antigene psa - Google Patents

Inhibiteurs de l'activite enzymatique de l'antigene psa

Info

Publication number
EP0944594A4
EP0944594A4 EP97952334A EP97952334A EP0944594A4 EP 0944594 A4 EP0944594 A4 EP 0944594A4 EP 97952334 A EP97952334 A EP 97952334A EP 97952334 A EP97952334 A EP 97952334A EP 0944594 A4 EP0944594 A4 EP 0944594A4
Authority
EP
European Patent Office
Prior art keywords
psa
inhibitors
enzymatic activity
enzymatic
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97952334A
Other languages
German (de)
English (en)
Other versions
EP0944594A1 (fr
Inventor
Benjamin A Anderson
Gerald W Becker
James A Carty
Nancy K Harn
Lowell D Hatfield
Blake L Neubauer
John R Rizzo
Tony Y Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0944594A1 publication Critical patent/EP0944594A1/fr
Publication of EP0944594A4 publication Critical patent/EP0944594A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP97952334A 1996-12-13 1997-12-09 Inhibiteurs de l'activite enzymatique de l'antigene psa Withdrawn EP0944594A4 (fr)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US3317996P 1996-12-13 1996-12-13
US33179P 1996-12-13
US4036297P 1997-03-13 1997-03-13
US4054397P 1997-03-13 1997-03-13
US4403297P 1997-03-13 1997-03-13
US4053997P 1997-03-13 1997-03-13
US40539P 1997-03-13
US44032P 1997-03-13
US40543P 1997-03-13
US40362P 1997-03-13
US4080597P 1997-03-18 1997-03-18
US4080497P 1997-03-18 1997-03-18
US40805P 1997-03-18
US40804P 1997-03-18
US4705497P 1997-05-19 1997-05-19
US4705597P 1997-05-19 1997-05-19
US47054P 1997-05-19
US47055P 1997-05-19
US5072197P 1997-06-25 1997-06-25
US50721P 1997-06-25
PCT/US1997/022573 WO1998025895A1 (fr) 1996-12-13 1997-12-09 Inhibiteurs de l'activite enzymatique de l'antigene psa

Publications (2)

Publication Number Publication Date
EP0944594A1 EP0944594A1 (fr) 1999-09-29
EP0944594A4 true EP0944594A4 (fr) 2000-05-03

Family

ID=27580753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97952334A Withdrawn EP0944594A4 (fr) 1996-12-13 1997-12-09 Inhibiteurs de l'activite enzymatique de l'antigene psa

Country Status (9)

Country Link
EP (1) EP0944594A4 (fr)
JP (1) JP2002514197A (fr)
KR (1) KR20000069431A (fr)
AU (1) AU5597098A (fr)
BR (1) BR9714394A (fr)
CA (1) CA2274958A1 (fr)
HU (1) HUP0000288A3 (fr)
IL (1) IL130300A0 (fr)
WO (1) WO1998025895A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP1443963B1 (fr) 2001-10-22 2014-05-21 The Scripps Research Institute Composes de ciblage d'anticorps
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
WO2005016326A2 (fr) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
CN1867331B (zh) 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
WO2005063704A1 (fr) * 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. Composes cycliques d'azetidine et medicaments les renfermant
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
WO2012003436A1 (fr) * 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Procédés permettant de traiter le trouble de stress post-traumatique
EP2613630A4 (fr) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Fluorocétolides formant des liaisons hydrogène pour traiter les maladies
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
WO2019055913A1 (fr) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. Compositions et procédés pour le traitement d'une lésion cérébrale
WO2026060400A1 (fr) * 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Polythérapies avec des modulateurs de kras
WO2026060384A1 (fr) * 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Polythérapies avec modulateurs de kras

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018164A1 (fr) * 1993-02-01 1994-08-18 The Research Foundation Of State University Of New York PROCEDE DE PREPARATION DE DERIVES DE TAXANE ET INTERMEDIAIRES DE β-LACTAME UTILISES A CET EFFET

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018164A1 (fr) * 1993-02-01 1994-08-18 The Research Foundation Of State University Of New York PROCEDE DE PREPARATION DE DERIVES DE TAXANE ET INTERMEDIAIRES DE β-LACTAME UTILISES A CET EFFET

Also Published As

Publication number Publication date
CA2274958A1 (fr) 1998-06-18
EP0944594A1 (fr) 1999-09-29
HUP0000288A3 (en) 2001-04-28
KR20000069431A (ko) 2000-11-25
AU5597098A (en) 1998-07-03
HUP0000288A2 (hu) 2001-01-29
JP2002514197A (ja) 2002-05-14
IL130300A0 (en) 2000-06-01
BR9714394A (pt) 2000-05-16
WO1998025895A1 (fr) 1998-06-18

Similar Documents

Publication Publication Date Title
IL130300A0 (en) Inhibitors of the enzymatic activity of PSA
PL326420A1 (en) Inhibitors of rotamase enzymatic activity
PL323381A1 (en) Rotamase enzymatic activity inhibitors
HU9603475D0 (en) Inhibitors of interlaukin-1beta converting enzyme
LT98002A (en) Inhibitors of rotamase enzyme activity
AP9700973A0 (en) Inhibitors of IMPDH enzyme
ZA973397B (en) Inhibitors of IMPDH enzyme.
IL108075A0 (en) Enzyme inhibitors
AP9701054A0 (en) Inhibitors of cycteine protease
IL138387A0 (en) Enzyme inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
PL328665A1 (en) Inhibitors of serinic protease
AU3107795A (en) Inhibitors of the benzamidine type
GB9425701D0 (en) Enzyme inhibitors
AU2277597A (en) New inhibitors of sh2-mediated processes
GB9816358D0 (en) Enzyme inhibitors
GB9502985D0 (en) Enzyme inhibitors
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
ZA934970B (en) Enzyme inhibitors
GB9617184D0 (en) Enzyme
ZA968982B (en) Inhibitors of rotamase enzyme activity
GB9713139D0 (en) Use of enzymes
ZA968981B (en) Inhibitors of rotamase enzyme activity.
ZA949525B (en) Enzyme inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990609;LT PAYMENT 19990609;LV PAYMENT 19990609;RO PAYMENT 19990609;SI PAYMENT 19990609

A4 Supplementary search report drawn up and despatched

Effective date: 20000316

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010726